GLP-1 receptor agonists increase serotonin turnover in the brain, meaning more serotonin is being released, utilized, and recycled
Pharmacodynamically, tirzepatide is an imbalanced co-agonist, favoring GIPR over GLP-1R, with a comparable affinity for GIPR as endogenous GIP and marginally lesser affinity for GLP-1R than endogenous GLP-1
Participants included adults with diabetes and adults without diabetes
268 In a randomized controlled trial of a multi-strain L
Vtama is an aryl hydrocarbon receptor agonist, the exact mechanism of action for which has yet to be completely elucidated, according to the drugs label
GLP-1: The Cancer Killing Engine The study also demonstrates that GLP-1's primary role in weight loss is not necessary for the restored ability of NK cells to fight cancer, suggesting that the medication is likely directly igniting the NK cells' engine